Thursday, 21 Sep 2017

You are here

The RheumNow Week in Review – 14 July 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

  1. FDA has announced Arthritis Advisory Hearing on Aug 2nd (Sirukumab in RA) and Aug 3rd (Tofacitinib in PsA) http://buff.ly/2uiBRM7
  2. Metanalyses suggest a decreasing risk of CVD in rheumatoid arthritis after 2000 http://buff.ly/2vgC3Zu
  3. Monitoring IgG4 related disease w/ ESR CRP IgG4 levels not reliable. but imaging w/ 18F-FDG PET/CT reflects activity http://buff.ly/2tiFk9132
  4. SLE nephritis & 64 controls show pregnancy on lupus nephritis does not increase SLE flares, renal outcomes or CKD https://t.co/gK1lzJTZc9
  5. NEJM Study >73K shows Improved diet quality over 12 yrs associated w/ decreased risk of death (7-17% less mortality) https://t.co/2MOTfTiFPs
  6. Baricitinib gets market approval in Japan (https://t.co/9c0JmNMWjq) & NICE recommends Oluminant for UK approval (https://t.co/2Zchi0Kev3)
  7. IOM review shows uninsured have poorer health & shortened lives;Concludes health insurance reduces the risk of death https://t.co/0ndNNGzIoV
  8. Warnings section of the OTEZLA (apremilast) label updated to include risk of severe diarrhea, nausea, and vomiting. https://t.co/ljdKlcUlPbRT
  9. Population study of 40K Dutch finds ACPA positivity in 1%; assoc w/ age, smoking, female & RA;but only 15-20% had RA https://t.co/96DvKWPYTL
  10. increased pregnancy-induced type I IFN-inducible gene expression observed in preg RA women who improved during preg https://t.co/VwFrpH18YGRT
  11. Orencia Approved for Use in Psoriatic Arthritis  
  12. Alendronate Use in Steroid Treated Patients Lowers the Risk of Hip Fracture
  13. Withdrawal of TNF Inibitors Fails in Most RA Patients
  14. Statins Improve Survival in Ankylosing Spondylitis

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Jack-I may have mentioned this in the past but again wonder if the improvement of CVD in RA patients may be a result of the markedly decreased use of NSAIDs as background therapy in RA patients on cDMARDs and bDMARDs since 2000.-D,Knapp
I think yours is a very valid point as research has shown a definite decline in NSAID use after the VIOXX/Cox-2 FDA hearing. But are rheums using more low dose prednisone instead? Researchers should control for these issues in their analyses. Good Point! JC

More Like This

CDC: 40% of U.S Adults Claim to Have Arthritis

The CDC has reported its 2013 and 2014 prevalence statistics for arthritis and other chronic medical conditions affecting U.S. adults aged ≥18 years. Data is drawn from the ongoing Behavioral Risk Factor Surveillance System (BRFSS), a state-based, telephone survey of noninstitutionalized adults. Data herein is self-reported arthritis (OA, RA, Gout, FM) and is quantified by state and metropolitan areas.

15 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

Why Rheumatologists Should Do Better Vaccinating this Flu Season

It is well known that influenza infection is more common in patients with rheumatologic diseases. Blumentals et al. showed that patients with rheumatoid arthritis are at increased risk for influenza regardless of DMARD/biologic use and may have a 2.75-fold increased incidence of related complications (https://buff.ly/2gYNTSz).

8 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes trends in MTX use and outcomes, fibromyalgia as an inflammatory disorder, drugs that stop psoriasis pruritus, drugs that don't cause TB, cardiovascular risk, and what Rheums think of ACR/EULAR criteria.

1 September 2017: The RheumNow Week in Review

This week's report includes new data on IL-1 inhibition and protection from CV events and lung cancer, baricitinib given a reprieve, and features on infections: HBV, shingles and mortality of septic arthritis.